Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome.

doi:10.1080/13693780801968571

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Candida lusitaniae fungemia in cancer patients: risk factors for amphotericin B failure and outcome.

Medical mycology - 1 Sept 2008

Atkinson Bradley J, Lewis Russell E, Kontoyiannis Dimitrios P

Abstract excerpt

Candida lusitaniae, a Candida species frequently resistant to amphotericin B (AMB), is a rare cause of candidemia. The clinical significance of this in vitro resistant phenotype, the risk factors for, and the clinical presentation of C. lusitaniae fungemia in comparison with those of Candida albicans have not been completely characterized. We reviewed 13 consecutive cases of C. lusitaniae fungemia in cancer...

Topics

Adult
Aged
Amphotericin B
Antifungal Agents
Candida
Candidiasis
Drug Resistance, Fungal
Female
Fungemia
Humans
Male
Middle Aged
Mutation
Neoplasms
Retrospective Studies
Risk Factors
Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 19180749
DOI: 10.1080/13693780801968571

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics